Jefferies & Co upgraded Sarepta Therapeutics (NASDAQ:SRPT) from Underperform to Hold in a statement released earlier today.
- Updated: September 19, 2016
Showing a price of $48.94, Sarepta Therapeutics (NASDAQ:SRPT) traded 91.30% higher on the day. The last stock price is up 163.13% from the two hundred day average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the date range. SRPT has registered a 50-day average of $26.16 and 200-day moving average of $20.47. 29,541,278 shares of the stock exchanged hands, up from ann average volume of 2,328,380
Jefferies & Co has upgraded Sarepta Therapeutics(NASDAQ:SRPT) from Underperform to Hold in a statement released Monday September 19 2016.
On Friday July 22 2016, Needham released a statement on Sarepta Therapeutics(NASDAQ:SRPT) bumped the target price from $20.00 to $26.00. At the time, this suggested an upside of 0.15%.
See Graphic Below:
A total of 13 firms have released a research note on SRPT. Three firms rate the company a strong buy, one firm rate the stock a buy, five firms rate the stock a hold, four analysts rate the company to underperform, and lastly one analystrate the company as sell with a one year target stock price of $20.77
Sarepta Therapeutics has a one-year low of $8.00 and a 52 week high of $56.18. The company’s market capitalization is presently $0.0.
Brief Synopsis On Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, and is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.